Does Rallies show Form 4 insider transactions for PTCT?

Yes. Rallies tracks PTCT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is PTCT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PTCT. It does not provide personalized investment advice.

PTCT (PTC Therapeutics, Inc.) Stock Analysis - Insider Trades

PTC Therapeutics, Inc. (PTCT) is a publicly traded Healthcare sector company. As of May 21, 2026, PTCT trades at $71.52 with a market cap of $5.82B and a P/E ratio of -28.67. PTCT moved +0.78% today. Year to date, PTCT is -7.48%; over the trailing twelve months it is +50.47%. Its 52-week range spans $34.57 to $87.50. Analyst consensus is strong buy with an average price target of $93.10. Rallies surfaces PTCT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading PTCT stock inside the company?

Recent PTCT insider activity includes Klein Matthew B. sold 679, Klein Matthew B. sold 7.22K, Klein Matthew B. sold 2.10K, Klein Matthew B. sold 2.57K, and Boulding Mark Elliott sold 840. Rallies tracks insider transaction dates, shares, prices, and estimated values.

PTCT Key Metrics

Key financial metrics for PTCT
Metric	Value
Price	$71.52
Market Cap	$5.82B
P/E Ratio	-28.67
EPS	$-2.48
Dividend Yield	0.00%
52-Week High	$87.50
52-Week Low	$34.57
Volume	331
Avg Volume	0
Revenue (TTM)	$827.11M
Net Income	$-186.73M
Gross Margin	0.00%

Recent PTCT Insider Trades

Klein Matthew B. sold 679 (~$49.61K) on May 14, 2026.
Klein Matthew B. sold 7.22K (~$527.71K) on May 14, 2026.
Klein Matthew B. sold 2.10K (~$153.47K) on May 14, 2026.
Klein Matthew B. sold 2.57K (~$186.37K) on May 14, 2026.
Boulding Mark Elliott sold 840 (~$65.71K) on May 8, 2026.

Latest PTCT News

PTC Therapeutics Raises 2026 Revenue Guidance to $750M–$850M After $272.6M Q1 Sales — May 8, 2026
PTC Therapeutics slides as 24-month Huntington’s data disappoints on statistical significance — Apr 29, 2026
PTC Therapeutics Reports 52% Progression Slowing at 10 mg in 24-Month PIVOT-HD Study — Apr 28, 2026
PTC Therapeutics to Share 24-Month PIVOT-HD Extension Data Supporting Phase 3 INVEST-HD — Apr 28, 2026
PTC Therapeutics climbs as traders look ahead to May 7 Q1 results call — Apr 27, 2026

PTCT Analyst Consensus

13 analysts cover PTCT: 0 strong buy, 10 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $93.10.

Common questions about PTCT

Who is trading PTCT stock inside the company?: Recent PTCT insider activity includes Klein Matthew B. sold 679, Klein Matthew B. sold 7.22K, Klein Matthew B. sold 2.10K, Klein Matthew B. sold 2.57K, and Boulding Mark Elliott sold 840. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for PTCT?: Yes. Rallies tracks PTCT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is PTCT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PTCT. It does not provide personalized investment advice.